Tech Company Inital Public Offerings
Synthorx IPO
On 12/6/2018, Synthorx became a public company.
Transaction Overview
Company Name
Announced On
12/6/2018
Transaction Type
IPO
Amount
$130,900,000
Proceeds Purpose
Proceeds will be used as follows: approximately $60.0 million to fund development of THOR-707 through dose escalation and expansion trials as a single agent and in combination with an immune checkpoint inhibitor; approximately $10.0 million to fund development of our IL-2 AI Synthorin, including completion of IND enabling studies and the initiation of a single ascending dose study; approximately $10.0 million to fund development of our IL-10 Synthorin into preclinical development and first-in-human clinical trials; and the remaining proceeds to fund our development of our IL-15 Synthorin, as well as advancing our earlier stage undisclosed cytokine programs and other general corporate purposes, which may include the hiring of additional personnel, capital expenditures and the costs of operating as a public company.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
11099 North Torrey Pines Rd. 290
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Website
Email Address
Overview
Synthorx is a biotechnology company using synthetic biology to discover and develop novel therapeutics, diagnostics and vaccines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Laura Shawver
Chief Scientific Officer
Marcos Milla
Chief Scientific Officer
Floyd Romesberg
Browse more venture capital transactions:
Prev: 12/6/2018: Contentful venture capital transaction
Next: 12/6/2018: Facilio venture capital transaction
Share this article
News on VC Transactions
We document every notable VC transaction. VC transactions on this site come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs